Biostem, Inc. Rated 'Speculative/3' By Investrend Research Analyst Daniel Capo, CFA.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- (Investrend Research Syndicate) Biostem Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : BTEM) has been rated 'Speculative / 3' in an initiating Benchmark report by Investrend Research analyst Daniel Capo, CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. , based on the "expectation of a successful closing of Biostem's pending merger with Cryobanks International." The analyst also stated: Cryobanks is positioned to benefit from the growing cord blood banking business both for non related donors and the personal storage business. In addition, the company is generating sales from the licensing of its proprietary processes, and is also engaged in research partnerships with groups developing stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. therapeutics. This multifaceted structure should allow Cryobanks to outperform its peers who are exclusively dedicated to the personal storage business. The recent passing into law of the "Stem Cell Therapeutic and Research Act of 2005, will provide $265 million for research in stem cell therapies stem cell therapy Cell therapy Molecular medicine A technology in which a person's own cells–eg, neuronal stem cells are triggered to revert to their primitive embryonic form, then redifferentiate into mature cells of various organs , cord blood cord blood n. Blood present in the umbilical vessels at the time of delivery. and bone marrow transplants bone marrow transplant: see bone marrow. . Included in this amount, $79 million is authorized for the collection and storage of cord blood stem cells cord blood stem cells Umbilical cord blood Hematology A therapeutic 'agent' containing concentrated hematopoietic stem cells for Pts with BM depleted–'wiped out' by disease; they are transfused into HLA-identical siblings and used to reconstitute the BM of with the goal of reaching a total inventory of 150,000 units. Cryobanks intends to be at the center of this growth and its goal is to be the largest provider of cord blood units in the world. Cryobanks has a license agreement with Pharmastem Therapeutics for certain technologies related to cord blood processing. For the 10 months ending 10/31/2005, total revenues were $393,394, down from $413,287 in the comparable 2004 period. The company recorded 147 personal storage fees and 1606 annual renewal fees. Total net loss was $3,435,043 up from $2,269,105. Total operating expenses Operating expenses The amount paid for asset maintenance or the cost of doing business, excluding depreciation. Earnings are distributed after operating expenses are deducted. are running about $340,000 per month or $4M per year. We believe that the company will need to raise additional funds in 2007. The full report is located at http://www.investrendresearch.com. An InvestorPower(TM) page has been created regarding the company at http://www.investrend.com/company/list.asp?sPathParam=yes. Investrend Research has been the leading independent equity research publishing and distribution program since 1996, with over 75 qualified professional analysts posting more than 1,000 reports to date. Anyone may enroll a company. Enrollment fees for the Benchmark research platform are $24,800, which are being paid by Equities Magazine, a third party. Analysts are paid in advance for their initial reports by Investrend Research to limit or eliminate pecuniary interests, and no one associated with the program may own or trade in the equities of companies under coverage. The company's research has also been enrolled in the investor-monitoring program by the Shareholders Research Alliance (http://www.shareholdersresearch.com), established to eliminate conflict and bias, and Investrend subscribes to the exacting "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com Anyone interested in receiving alerts regarding Biostem research or webcasts should e-mail contact@investrend.com with "BTEM" in the subject line, or click on http://www.investrend.com/contact.asp. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion